SUMAtriptan Succinate Syringe injection

Generic name: Sumatriptan succinate

Drug class: Selective 5-HT1B/1D receptor agonist

Dosage form: Injection

Root of administration: Subcutaneous injection

Dose: 4 mg to 6 mg per injection; maximum cumulative dose of 12 mg within 24 hours, administered as two 6 mg doses separated by at least 1 hour

Mechanism of action: Sumatriptan succinate is a selective 5-HT1B/1D receptor agonist that constricts intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, thereby alleviating migraine and cluster headache symptoms.

Drug usage cases:

• Acute treatment of migraine attacks, with or without aura
• Acute treatment of cluster headache attacks

Drug contraindications:

• Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia)
• Coronary artery vasospasm, including Prinzmetal’s angina
• Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
• History of stroke or transient ischemic attack (TIA)
• Hemiplegic or basilar migraine
• Peripheral vascular disease
• Uncontrolled hypertension
• Recent use (within 24 hours) of ergotamine-containing medications, ergot-type medications (such as dihydroergotamine or methysergide), or another 5-HT1 agonist
• Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor
• Hypersensitivity to sumatriptan (angioedema and anaphylaxis have been reported)
• Severe hepatic impairment

Side effects:

• Injection site reactions (pain, redness, swelling)
• Tingling or numbness
• Dizziness or vertigo
• Warm or hot sensations
• Burning or pressure sensations
• Flushing
• Feeling of tightness
• Chest discomfort or tightness
• Fatigue
• Throat discomfort
• Muscle pain or cramps
• Altered taste
• Visual disturbances
• Elevated blood pressure
• Serotonin syndrome (rare but serious) characterized by agitation, hallucinations, rapid heartbeat, high or low blood pressure, fever, nausea, vomiting, diarrhea, muscle rigidity, dizziness, tremor, seizures, and coma

Warnings:

• Use with caution in patients with risk factors for cardiovascular disease
• Monitor blood pressure regularly during treatment
• Discontinue use if signs of serotonin syndrome occur
• Avoid use in patients with a history of hemiplegic or basilar migraine due to increased risk of stroke
• Not recommended for the prevention of migraine or cluster headache attacks
• Use only if a clear diagnosis of migraine or cluster headache has been established
• Do not exceed the maximum recommended dose or frequency of administration
• Ensure proper injection technique to minimize injection site reactions
• Be aware of potential drug interactions, especially with other 5-HT1 agonists, ergotamine derivatives, and MAO-A inhibitors

Use during pregnancy or breastfeeding:

Sumatriptan succinate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether sumatriptan is excreted in human milk; therefore, caution should be exercised when administering to a nursing woman. Consult a healthcare provider for personalized advice.